These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19709516)

  • 1. Control of risk factors in and treatment of patients with coronary heart disease: the TRECE study.
    Bertomeu V; Cordero A; Quiles J; Mazón P; Aznar J; Bueno H
    Rev Esp Cardiol; 2009 Jul; 62(7):807-11. PubMed ID: 19709516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in medical treatment of chronic coronary heart disease patients according to medical specialities.
    Cordero A; Bertomeu-Martínez V; Mazón P; Quiles J; Aznar J; Bueno H
    Cardiovasc Ther; 2009; 27(3):173-80. PubMed ID: 19689616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-to-practice gaps in the management of community-dwelling Australian patients with ischaemic heart disease.
    Schmid O; Chalmers L; Bereznicki L
    J Clin Pharm Ther; 2015 Aug; 40(4):398-403. PubMed ID: 25924028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How beta-blockers are used in Spain? Analysis of limitations in their use in internal medicine and cardiology: CARACTER-BETA study].
    Garcia-Moll X; Fácila L; Conthe P; Zapata A; Artigas R; Bertomeu V; González-Juanatey JR;
    Rev Esp Cardiol; 2011 Oct; 64(10):883-90. PubMed ID: 21885180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
    Resor CD; Nathan A; Kereiakes DJ; Yeh RW; Massaro JM; Cutlip DE; Gabriel Steg P; Hsieh WH; Mauri L;
    Circulation; 2016 Oct; 134(14):989-998. PubMed ID: 27576774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.
    Kocas C; Abaci O; Oktay V; Coskun U; Bostan C; Yildiz A; Arat Ozkan A; Gurmen T; Ersanli M
    J Clin Pharm Ther; 2013 Dec; 38(6):476-9. PubMed ID: 23992279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):102-110. PubMed ID: 29394340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease.
    Meurice T; Tricot O; Lemesle G; Deneve M; Lejeune P; Biausque F; Cordier C; Savoye C; Hennebert O; Taghipour K; Sivery B; Pruvost P; Alaoui M; Carpentier L; Segrestin B; Lamblin N; Bauters C
    Arch Cardiovasc Dis; 2015; 108(6-7):340-6. PubMed ID: 25858539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction.
    Bramlage P; Messer C; Bitterlich N; Pohlmann C; Cuneo A; Stammwitz E; Tebbenjohanns J; Gohlke H; Senges J; Tebbe U
    Heart; 2010 Apr; 96(8):604-9. PubMed ID: 20353936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Lindahl B; Baron T; Erlinge D; Hadziosmanovic N; Nordenskjöld A; Gard A; Jernberg T
    Circulation; 2017 Apr; 135(16):1481-1489. PubMed ID: 28179398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of medical treatment for peripheral arterial disease in Chinese high-risk patients.
    Hasimu B; Li J; Yu J; Ma Y; Zhao M; Nakayama T; Ma W; Yang J; Zheng L; Li X; Luo Y; Xu Y; Zhang L; Zou L; Xiao W; Han Y; Hu D
    Circ J; 2007 Jan; 71(1):95-9. PubMed ID: 17186985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors and Outcomes of Routine Versus Optimal Medical Therapy in Stable Coronary Heart Disease.
    Chun S; Qiu F; Austin PC; Ko DT; Mamdani M; Wijeysundera DN; Czarnecki A; Bennell MC; Wijeysundera HC
    Am J Cardiol; 2015 Sep; 116(5):671-7. PubMed ID: 26119653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current standard of care in patients affected by coronary heart disease in Italy: the MC'95 study.
    Magnani B; Dal Palù C; Zanchetti A;
    Ital Heart J; 2002 Feb; 3(2):86-95. PubMed ID: 11926017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
    Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of asymptomatic carotid stenosis despite optimal medical therapy.
    Conrad MF; Boulom V; Mukhopadhyay S; Garg A; Patel VI; Cambria RP
    J Vasc Surg; 2013 Jul; 58(1):128-35.e1. PubMed ID: 23806255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current management and treatment of patients with stable coronary artery diseases presenting to cardiologists in different clinical contexts: A prospective, observational, nationwide study.
    De Luca L; Temporelli PL; Lucci D; Gonzini L; Riccio C; Colivicchi F; Geraci G; Formigli D; Maras P; Falcone C; Di Lenarda A; Gulizia MM;
    Eur J Prev Cardiol; 2018 Jan; 25(1):43-53. PubMed ID: 29124952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland.
    Sigurdsson EL; Jónsson JS; Thorgeirsson G
    Scand J Prim Health Care; 2002 Mar; 20(1):10-5. PubMed ID: 12086276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease management programmes for patients with coronary heart disease--an empirical study of German programmes.
    Gapp O; Schweikert B; Meisinger C; Holle R
    Health Policy; 2008 Dec; 88(2-3):176-85. PubMed ID: 18442868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical and sociodemographic factors predict persistent smoking after coronary events.
    Sverre E; Otterstad JE; Gjertsen E; Gullestad L; Husebye E; Dammen T; Moum T; Munkhaugen J
    BMC Cardiovasc Disord; 2017 Sep; 17(1):241. PubMed ID: 28877684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction.
    Böhm M; Tschöpe C; Wirtz JH; Lokies J; Turgonyi E; Bramlage P; Lins K; Strunz AM; Tebbe U
    Clin Cardiol; 2015 Apr; 38(4):200-7. PubMed ID: 25733185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.